KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Investing Activities (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Cash from Investing Activities data on record, last reported at $19.3 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 5353.53% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $99.5 million, up 219.46%, while the annual FY2025 figure was $99.5 million, 219.46% up from the prior year.
  • Cash from Investing Activities reached $19.3 million in Q4 2025 per PCRX's latest filing, down from $43.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $66.9 million in Q4 2021 and bottomed at -$208.0 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is -$7.6 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: crashed 1101.36% in 2024, then skyrocketed 5353.53% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $66.9 million in 2021, then plummeted by 83.28% to $11.2 million in 2022, then decreased by 25.16% to $8.4 million in 2023, then plummeted by 104.39% to -$368000.0 in 2024, then surged by 5353.53% to $19.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $19.3 million in Q4 2025, $43.6 million in Q3 2025, and $62.2 million in Q2 2025.